5 Major Benefits of Vero Vaccine Development Pipelines
Rapid virus evolution challenges the medical industry with new strains every year. The Vero cell platform meets these challenges with a streamlined system for the rapid development of novel vaccines. The platform has proven effective at developing vaccines for SARS, avian influenza and other evolving threats, for the following [...]
Blow-Fill-Seal
This innovative process mitigates risks associated with the sterile biologics manufacturing. However, tight control of parameters is critical. The risk of contamination is always present throughout any pharmaceutical manufacturing pipeline. That risk is particularly acute in biologics fill and finish. For that reason, a growing number of biologic manufacturers are [...]
Injectable Biologic Formulation Development
The field has advanced considerably in recent years, but a number of key challenges remain. by Raymond E Peck, CEO of VxP Biologics Because injectable biologics are introduced directly into the body’s tissues, these formulations must be extraordinarily free from contamination of every kind. This requirement sets a high bar [...]
Sterile Biologics Manufacturing
The correct choice of sterilized packaging is crucial, as is regulatory compliance. by Raymond E Peck, CEO of VxP Biologics While the potency and efficacy of active pharmaceutical ingredients (APIs) remain crucial in biologics manufacturing, the packaging of those drugs is equally critical in ensuring safety and stability. A wide [...]
Flow Cytometry
This powerful technique enables rapid identification and sorting of cells, streamlining the manufacture of many biologic pharmaceuticals. by Raymond E Peck, CEO of VxP Biologics In the manufacture of many types of biologics, flow cytometry is a crucial tool for identifying, analyzing and sorting cells. This technique can provide a [...]
The Vero Vaccine Production Pipeline
The Vero platform’s upstream and downstream processing stages are designed for maximum efficiency and safety, as well as purity of the final product. Despite many recent advances in vaccine development technology, the actual process of bringing new vaccines to the clinical trial stage often remains cumbersome and slow. Even the most elaborate recombinant technologies and vector systems may not integrate smoothly into an existing manufacturing pipeline, and inefficiencies and safety issues may emerge at any step of the process.